Travere Therapeutics Hits New 52-Week High of $35.34, Marking Major Growth

Travere Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 35.34 on October 31, 2025. This achievement underscores the company's remarkable performance over the past year, with a staggering 383.63% increase compared to the S&P 500's 19.89% gain during the same period.
The company's market capitalization stands at USD 1,890 million, reflecting its position within the small-cap category. Despite being loss-making, Travere has shown impressive growth in net sales, reporting a 40.03% increase, and has delivered positive results for three consecutive quarters. Key financial metrics include an operating cash flow of USD -115.44 million and a net sales figure of USD 114.45 million, indicating robust operational activity.

With a price-to-book ratio of 57.71 and a debt-to-equity ratio of 2.01, Travere Therapeutics continues to navigate its financial landscape while achieving notable performance metrics. The stock's journey from a 52-week low of USD 12.91 to its current high reflects its dynamic growth trajectory in the competitive biotechnology market.